|
|
Volumn 11, Issue 4, 2012, Pages 260-
|
|
Deal watch: Biogen acquires Stromedix to pursue novel fibrosis therapy
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHAVBETA6 INTEGRIN;
BIOLOGICAL MARKER;
MONOCLONAL ANTIBODY;
STX 100;
TRANSFORMING GROWTH FACTOR BETA;
UNCLASSIFIED DRUG;
CLINICAL FEATURE;
DRUG EFFECT;
DRUG MECHANISM;
DRUG RESEARCH;
DRUG SAFETY;
DRUG TARGETING;
DRUG TOLERABILITY;
EVIDENCE BASED MEDICINE;
FIBROSING ALVEOLITIS;
HUMAN;
NONHUMAN;
PRIORITY JOURNAL;
PROGNOSIS;
PROTEIN EXPRESSION;
PROTEIN FUNCTION;
PROTEIN PROTEIN INTERACTION;
PROTEIN SYNTHESIS INHIBITION;
SHORT SURVEY;
ANIMALS;
CLINICAL TRIALS, PHASE I AS TOPIC;
CLINICAL TRIALS, PHASE II AS TOPIC;
DRUG DISCOVERY;
DRUG INDUSTRY;
FIBROSIS;
HUMANS;
|
|
EID: 84859369630
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3708 Document Type: Short Survey |
|
Times cited : (2)
|
|
References (0)
|
